LMR Partners’s NovoCure NVCR Stock Holding History

LMR Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,700	Closed	-$75.9K	–	1086
2023 Q3	$75.9K	Buy	+4,700	New	+$136K	﹤0.01%	696

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

LMR Partners's NVCR Position: Q1 2025 in Review

LMR Partners sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 32,914 shares — an estimated $981K sold.

LMR Partners first reported a position in NVCR in Q3 2019 and held it in 8 quarters. The position peaked at $8.11M in Q3 2022. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

LMR Partners reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
LMR Partners sold 32,914 NovoCure shares in Q1 2025, an estimated $981K.
LMR Partners first reported a position in NovoCure in Q3 2019 and held it in 8 quarters.
LMR Partners's NovoCure position peaked at $8.11M in Q3 2022.
227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.